DelveInsight’s “Primary Biliary Cholangitis (PBC) Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Primary Biliary Cholangitis market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).
The report covers emerging Primary Biliary Cholangitis drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current Primary Biliary Cholangitis treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Primary Biliary Cholangitis (PBC): An Overview
According to the American Liver Foundation, primary biliary cholangitis (PBC), formerly known as primary biliary cirrhosis, is a chronic liver disease resulting from the progressive destruction of the bile ducts in the liver, called the intrahepatic bile ducts. Prolonged hepatic cholestasis subsequently leads to cirrhosis and portal hypertension.
Patients with Primary Biliary Cholangitis can be asymptomatic or may present with jaundice, pruritus, and fatigue. Other symptoms may include abdominal pain, skin darkening, and xanthomas or xanthelasmas. Individuals may also complain of dry mouth, eyes, bone, muscle, and joint pain. As the disease progresses, symptoms of cirrhosis can develop, including jaundice, edema, ascites, and varices.
Various research has indicated associated environmental trigger in animal models, which includes urinary tract infection, reproductive hormone replacement, nail polish, cigarette smoking and xenobiotics, and toxic waste sites. The inflammation results from a direct insult to environmental factors and toxins.
Primary Biliary Cholangitis (PBC) Market Key Facts
There were approximately 24,500 males and more than 111,000 females affected by Primary Biliary Cholangitis in the United States in 2021, and it is estimated that the prevalence will increase and reach up to nearly 33,000 males and 149,000 females by 2032.
Assessments showed that in EU4 and the UK, nearly 15,000 males and more than 90,500 females, respectively, were affected by Primary Biliary Cholangitis in 2021, which is expected to increase during the forecast period (2022–2032).
Among EU4 and the UK, Germany had the highest number of diagnosed prevalent cases of Primary Biliary Cholangitis (around 32,000 cases) in 2021. On the other hand, Spain had the lowest number of diagnosed prevalent cases of PBC, with about 10,000 cases.
Assessments show that Japan had about 44,000 diagnosed prevalent cases of Primary Biliary Cholangitis in 2021.
Many molecules are in the pipeline to treat primary biliary cholangitis patients across many countries to cater to different therapeutic needs. Some of the major late-stage products are likely to hit the market in the upcoming years include seladelpar (CymaBay Therapeutics), elafibranor (Genfit), setanaxib (Genkyotex SA), saroglitazar Mg (Zydus), and linerixibat (GlaxoSmithKline).
The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted market size by analyzing the impact of current and emerging Primary Biliary Cholangitis pipeline therapies. It also thoroughly assesses the Primary Biliary Cholangitis market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.
The report gives complete details of the market trend for each marketed Primary Biliary Cholangitis drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competition with other therapies, brand value, and their impact on the market.
Primary Biliary Cholangitis (PBC) Epidemiology Assessment
The epidemiology section provides insights into the historical, current, and forecasted Primary Biliary Cholangitis epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted Primary Biliary Cholangitis epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pools, future trends, and views of key opinion leaders.
The Report Covers the Primary Biliary Cholangitis Epidemiology, Segmented as –
Total Diagnosed Prevalent Cases of PBC in the 7MM (2019–2032)
Gender-specific Cases of PBC in the 7MM (2019–2032)
Age-specific Cases of PBC in the 7MM (2019–2032)
Primary Biliary Cholangitis (PBC) Drugs Uptake and Pipeline Development Activities
The drug uptake section focuses on the uptake rate of potential drugs recently launched in the Primary Biliary Cholangitis market or expected to be launched during the study period. The analysis covers the Primary Biliary Cholangitis market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the market dynamics by drug sales, the most rapid drug uptake, and the reasons behind the maximal use of particular drugs. Additionally, it compares the Primary Biliary Cholangitis drugs based on their sale and market share.
The report also covers the Primary Biliary Cholangitis pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key Primary Biliary Cholangitis companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Learn How the Primary Biliary Cholangitis Market Will Evolve and Grow by 2032 @
Primary Biliary Cholangitis (PBC) Therapeutics Analysis
Several major pharma and biotech companies are developing therapies for Primary Biliary Cholangitis. Currently, Genfit is leading the therapeutics market with its Primary Biliary Cholangitis drug candidates in the most advanced stage of clinical development.
Primary Biliary Cholangitis (PBC) Companies Actively Working in the Therapeutics Market Include
Calliditas Therapeutics AB (Calliditas Therapeutics Suisse SA), Cara Therapeutics, Inc., Chemomab Ltd., Chia Tai Tianqing Pharmaceutical Group Co., Ltd., CymaBay Therapeutics, Eli Lilly and Company, Escient Pharmaceuticals, Future Medicine, Gannex Pharma, Genfit, Gilead Sciences, GlaxoSmithKline, Intercept Pharmaceuticals, Merck, Mirum Pharmaceuticals, MYR Pharma, Nanjing Chia-tai Tianqing Pharmaceutical, Ohara Pharmaceutical, Selecta Biosciences, Zydus Therapeutics, and many others.
Emerging and Marketed Primary Biliary Cholangitis (PBC) Therapies Covered in the Report Include:
Saroglitazar Magnesium: Zydus Discovery
TQA3526: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Seladelpar: CymaBay Therapeutics
And Many More
The Report Covers an In-depth Assessment of Emerging Drugs and key Companies. Download the Sample Report to Learn More @
Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. Primary Biliary Cholangitis Competitive Intelligence Analysis
4. Primary Biliary Cholangitis Market Overview at a Glance
5. Primary Biliary Cholangitis Disease Background and Overview
6. Primary Biliary Cholangitis Patient Journey
7. Primary Biliary Cholangitis Patient Population and Epidemiology Trends (In the US, EU5, and Japan)
8. Primary Biliary Cholangitis Treatment Algorithm, Current Treatment, and Medical Practices
9. Primary Biliary Cholangitis Unmet Needs
10. Key Endpoints of Primary Biliary Cholangitis Treatment
11. Primary Biliary Cholangitis Marketed Therapies
12. Primary Biliary Cholangitis Emerging Drugs and Latest Therapeutic Advances
13. Primary Biliary Cholangitis Seven Major Market Analysis
14. Attribute Analysis
15. Primary Biliary Cholangitis Market Outlook (In US, EU5, and Japan)
16. Primary Biliary Cholangitis Companies Active in the Market
17. Primary Biliary Cholangitis Access and Reimbursement Overview
18. KOL Views on the Primary Biliary Cholangitis Market
19. Primary Biliary Cholangitis Market Drivers
20. Primary Biliary Cholangitis Market Barriers
22. DelveInsight Capabilities
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Download the Sample PDF to Learn More About the Key Offerings of the Report @
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Other Trending Healthcare Reports by DelveInsight
“Dysthymia Market Insights, Epidemiology, and Market Forecast-2032” report deliver an in-depth understanding of the historical and forecasted epidemiology as well as the Dysthymia market size, share, trends, and growth analysis in the seven major markets (i.e. the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan. Moreover, it also covers the current treatment practices, emerging drugs, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the Dysthymia market.
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Address:304 S. Jones Blvd #2432
City: Las Vegas
Country: United States